A pharmaceutical product called TT-10, which spurs proliferation of heart muscle cells, was thought to offer promise to treat heart attacks. In a mouse heart-attack model several years ago, intraperitoneal injection of TT-10 at first promoted proliferation of heart muscle cells and showed declines in the size of the dead area of heart muscle. However, these early improvements were followed by worsened cardiac function at later time points. Now researchers show that a different delivery method, nanoparticle-mediated, slow-release of TT-10, enhances the potency and durability of TT-10 treatment for repair of heart muscle in the mouse heart-attack model.
from Top Health News -- ScienceDaily https://ift.tt/3pEHsst
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
While sales to original equipment manufacturers declined 16.3% year on year in FY20, the replacement market sales declined by a modest 2.6% ...
-
India's passenger vehicle sales are expected to grow between 3-5 percent in the current fiscal year, after expanding at the slowest pace...
-
The earnings momentum has been quite resilient and the policy momentum quite focused towards improving the infrastructure and attractiveness...
No comments:
Post a Comment